Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Gains from Investment Securities (2019 - 2024)

Historic Gains from Investment Securities for Vivos Therapeutics (VVOS) over the last 6 years, with Q4 2024 value amounting to $5000.0.

  • Vivos Therapeutics' Gains from Investment Securities fell 9418.6% to $5000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $111000.0, marking a year-over-year increase of 60454.55%. This contributed to the annual value of $31000.0 for FY2024, which is 9579.38% down from last year.
  • Per Vivos Therapeutics' latest filing, its Gains from Investment Securities stood at $5000.0 for Q4 2024, which was down 9418.6% from $105000.0 recorded in Q3 2024.
  • In the past 5 years, Vivos Therapeutics' Gains from Investment Securities ranged from a high of $3.2 million in Q2 2022 and a low of -$1.6 million during Q3 2023
  • For the 5-year period, Vivos Therapeutics' Gains from Investment Securities averaged around $1.4 million, with its median value being $1.9 million (2020).
  • As far as peak fluctuations go, Vivos Therapeutics' Gains from Investment Securities plummeted by 15521.05% in 2023, and later soared by 10656.25% in 2024.
  • Vivos Therapeutics' Gains from Investment Securities (Quarter) stood at $2.3 million in 2020, then increased by 24.72% to $2.9 million in 2021, then tumbled by 90.98% to $259000.0 in 2022, then crashed by 66.8% to $86000.0 in 2023, then crashed by 94.19% to $5000.0 in 2024.
  • Its last three reported values are $5000.0 in Q4 2024, $105000.0 for Q3 2024, and $14000.0 during Q2 2024.